Statement of Principles concerning analgesic nephropathy (Reasonable Hypothesis) (No. 43 of 2025)

This instrument is a Statement of Principles concerning analgesic nephropathy (Reasonable Hypothesis) (No. 43 of 2025), made by the Repatriation Medical Authority under subsection 196B(2) of the Veterans' Entitlements Act 1986, and commencing 19 May 2025 (see sections 1, 2 and 3). It replaces the prior Statement of Principles concerning analgesic nephropathy No. 77 of 2016 (section 4). The instrument is expressly stated to apply to claims to which section 120A of the VEA or section 338 of the Military Rehabilitation and Compensation Act 2004 applies (section 5). In functional terms the instrument sets the medical criteria that, if met and related to “relevant service”, are sufficient to raise a reasonable hypothesis that analgesic nephropathy or death from analgesic nephropathy is connected with a person’s service.

Mechanically, the Statement does three concrete things. First, it defines the disease for the purposes of claims processing: analgesic nephropathy is spelled out as a bilateral chronic renal disease characterised by papillary necrosis, chronic interstitial nephritis, renal cortical atrophy and capillary sclerosis, together with a clinical state of loss of renal function in a person with a history of consumption of large amounts of analgesic agents, and occurring in the absence of another biochemical, anatomical or metabolic cause (section 7(2)). The instrument notes that while the condition attracts ICD‑10‑AM code N14.0, the meaning for claims purposes is the textually specified definition (sections 7(2) and 7(3)). Second, the instrument describes when death is to be treated as death from analgesic nephropathy, namely where death from a terminal event or condition was contributed to by the person’s analgesic nephropathy (section 7(4)); the Schedule supplies a non-exhaustive list of terminal events (Schedule 1 - Dictionary). Third, the Statement identifies the minimum medical factors that must exist for a reasonable hypothesis of service connection: either defined quantitative phenacetin consumption thresholds or an inability to obtain appropriate clinical management before clinical worsening (section 9).

The instrument states the Repatriation Medical Authority’s view that there is sound medical‑scientific evidence indicating analgesic nephropathy and death from it can be related to relevant service (section 8). It then limits application to persons whose qualifying factors are related to “relevant service” as defined in the Schedule (section 10(1)). The Schedule defines “relevant service” as operational, peacekeeping, hazardous, British nuclear test defence service under the VEA, or warlike or non‑warlike service under the MRCA (Schedule 1 - Dictionary). The Statement clarifies interaction with other Statements of Principles: if a factor in section 9 refers to an injury or disease covered by another Statement, then the factors in that other Statement apply according to their terms (section 11).

The Statement does not itself create a new entitlement, payment mechanism, penalty or administrative process. It is framed as a medical assessment statement to be applied in the statutory claims processes under the VEA and the MRCA (sections 3 and 5). It sets threshold medical facts that decision‑makers will use to determine whether a “reasonable hypothesis” linking analgesic nephropathy or death from analgesic nephropathy to relevant service has been raised.

The instrument is short and focused on a narrow set of medical and evidential concepts that will be used in processing VEA and MRCA claims. Central concepts are defined in text and in Schedule 1 - Dictionary; the main ones are “analgesic nephropathy”, “relevant service”, and “terminal event”.

Analgesic nephropathy, as defined in subsection 7(2), is a morphological and clinical diagnosis. It requires both specific renal pathologies , papillary necrosis, chronic interstitial nephritis, renal cortical atrophy and capillary sclerosis , and a clinical state of loss of renal function in someone with a history of consumption of large amounts of analgesic agents, where another biochemical, anatomical or metabolic cause for renal impairment is absent. The Statement makes explicit that this statutory definition, not the ICD‑10‑AM code alone, governs the application (sections 7(2) and 7(3)). This dual requirement means that for claims work, both diagnostic descriptors and a consumption history are necessary elements of the medical picture the Statement contemplates.

Death from analgesic nephropathy is captured where a terminal event or condition was contributed to by analgesic nephropathy (section 7(4)). The Schedule lists representative terminal events, including pneumonia, respiratory failure, cardiac arrest, circulatory failure and cessation of brain function. These examples indicate how the instrument treats proximate causes of death where renal disease materially contributed.

The causal threshold the Statement addresses is the statutory “reasonable hypothesis”. The instrument identifies the minimum factual factors that must exist to raise that hypothesis: either quantified exposure to phenacetin in phenacetin‑containing analgesics, or inability to obtain appropriate clinical management for analgesic nephropathy before clinical worsening (section 9). The phenacetin criteria are numeric: a total of at least 1 kg of phenacetin before clinical onset, or an average of at least 1 g/day for a continuous period of at least two years immediately preceding clinical onset (section 9(1)(a) and (b)). The instrument includes notes explaining phenacetin’s formulation history and synonyms (Notes 1 and 2 to section 9).

The instrument makes “relevant service” an explicit gating condition (section 10(1) and Schedule 1). The Schedule lists six service types (a) through (f). The instrument also narrows the application of the “inability to obtain appropriate clinical management” factor: it applies only to material contribution to, or aggravation of, analgesic nephropathy where the person’s analgesic nephropathy was suffered or contracted before or during (but did not arise out of) the person’s relevant service (section 10(2)). This creates a temporal and causal limitation on how lack of clinical management during service can be used to establish material contribution or aggravation.

Directly affected persons are claimants asserting a connection between analgesic nephropathy (or death from it) and “relevant service” as those terms are used in the VEA and the MRCA (section 5 and Schedule 1 - Dictionary). “Relevant service” is narrowly defined to include operational, peacekeeping, hazardous, British nuclear test defence service under the VEA, or warlike or non‑warlike service under the MRCA (Schedule 1 - Dictionary). The Statement therefore affects veterans and former members whose service falls into those categories and who submit claims under section 120A of the VEA or section 338 of the MRCA (section 5).

The Repatriation Medical Authority is the declarant of the Statement (section 3). Decision‑makers who process entitlement claims under the VEA and MRCA will apply the Statement in assessing whether a reasonable hypothesis exists. The instrument does not itself name administrative decision‑makers, but its express legal foundation is subsection 196B(2) of the VEA (section 3), which is the statutory power under which the Authority makes Statements of Principles for use in claims assessment. The Statement therefore alters the evidence profile decision‑makers will evaluate when determining service connection for analgesic nephropathy claims.

Medical practitioners, forensic pathologists and other clinicians who prepare reports for claimants or for decision‑makers will be affected by the Statement’s definitional and factor requirements. The Statement specifies morphological and clinical descriptors to be established, and it introduces numeric thresholds for phenacetin exposure (section 7(2) and section 9(1)). Medical reports that do not address the listed morphological features, the consumption history, or the absence of other biochemical, anatomical or metabolic causes may be less useful to a claimant, because the Statement spells out which facts raise the reasonable hypothesis.

Legal advisers, advocates and claims preparers are also affected. The Statement creates discrete evidentiary tasks: establishing service type, establishing the presence of one or more of the factors in section 9, and proving a relationship between such factors and relevant service (section 10(1)). Where the claimed factor references an injury or disease covered by another Statement of Principles, advisers must locate and apply that other Statement (section 11).

Indirectly affected groups include institutions that hold historical dispensing, sales, or medical records. The phenacetin thresholds will make documentation of historical analgesic use directly valuable. The instrument’s notes name common phenacetin‑containing over‑the‑counter compound analgesics (for example, Bex powder, Vincent’s powder, Empirin Compound, and Bromo seltzer) and list synonyms for phenacetin (section 9 Note 1 and Note 2). Those historical product names and chemical synonyms will affect where claimants and their advisers look for evidence.

The Statement establishes no express civil duties or statutory rights in its own text beyond defining medical factors that must exist to raise a reasonable hypothesis. It is an evidentiary tool to be applied within the broader VEA and MRCA decision frameworks. Nonetheless, the Statement creates operational duties and procedural expectations for claimants, medical reporters and decision‑makers by setting mandatory criteria for reasonable hypothesis assessment.

For claimants, the effective duty is to adduce evidence of at least one of the section 9 factors and to show that the factor is related to relevant service under section 10(1). Section 9 provides that at least one of the listed factors must exist before a reasonable hypothesis can be said to be raised. The phenacetin thresholds are precise: total consumption of at least 1 kg of phenacetin in a phenacetin‑containing analgesic before clinical onset, or an average ingestion of at least 1 g/day of phenacetin for a continuous period of at least two years immediately preceding clinical onset (section 9(1)(a) and (b)). Claimants therefore must produce evidence that bears on these quantities or evidence supporting the alternative listed factor, namely inability to obtain appropriate clinical management before clinical worsening (section 9(2)). The Statement does not prescribe how those facts must be proved; proving them remains a procedural matter in claim assessment under the VEA/MRCA. The requirement that the factor be “related to the relevant service rendered by the person” (section 10(1)) imposes an additional relational requirement.

For clinicians and expert witnesses preparing reports, the Statement functions as a template of what medical facts should be addressed. Reports that speak directly to the morphological features in subsection 7(2), to a history of “consumption of large amounts of analgesic agents”, and to the absence of alternate biochemical, anatomical or metabolic causes, will be directly responsive. Likewise, an expert who addresses historical phenacetin exposure in the quantitative terms of section 9(1) will be giving the decision‑maker the precise material the Statement identifies.

For decision‑makers (statutory decision‑makers in the VEA and MRCA processes), the Statement is an authoritative articulation of the medical facts that will raise a reasonable hypothesis. It is made under the stated statutory authority (section 3) and applies to claims described in section 5. Decision‑makers therefore have the operational duty to have regard to this Statement when assessing whether the required medical connection has been raised. Where a factor in section 9 refers to an injury or disease covered by another Statement, decision‑makers must apply that other Statement’s factors as in force from time to time (section 11).

The instrument itself contains no penalties, fines, criminal offences or administrative sanctions. It is a Statement of Principles, made under subsection 196B(2) of the Veterans' Entitlements Act 1986 (section 3), designed to frame medical assessment in claims processes; it does not purport to create enforcement mechanisms or culpability for non‑compliance in the form of statutory sanctions.

Enforcement in the context of this instrument is procedural and administrative. The Statement will be used by decision‑makers processing claims under the VEA and MRCA (section 5) to determine whether a “reasonable hypothesis” linking analgesic nephropathy, or death from analgesic nephropathy, to relevant service has been raised. If a decision‑maker finds the necessary factors and relationship are present in accordance with the Statement, that finding informs the administrative determination of entitlement under the relevant Act. Conversely, if the factors or the relationship to relevant service are not established, a reasonable hypothesis will not be said to have been raised and entitlement may be declined. The instrument does not set the standards for appeal, review or judicial challenge; those are governed by the VEA, the MRCA and relevant administrative law, none of which are reproduced in this Statement.

There is no express inspection, reporting or procedural enforcement duty placed on third parties such as pharmacies, employers or health practitioners by this Statement. The instrument may, however, create practical demands on those parties because historical records and clinical management evidence will be relevant to proving the prescribed factors (for example, phenacetin consumption history or evidence of inability to obtain appropriate clinical management). The instrument does not mandate preservation of particular records or authorise compulsion to produce them; any such powers would arise from general powers in the VEA/MRCA claims process or other statutes outside this Statement.

The only direct operational or legal consequence contained in the instrument is repeal of the 2016 Statement of Principles concerning analgesic nephropathy (section 4). That repeal means the 2025 Statement replaces the 2016 Statement for the purposes of claims made after the commencement date. The instrument does not provide transitional provisions in the text provided; decision‑makers will need to apply existing statutory rules on the application of newer Statements to ongoing claims if such rules exist in the VEA/MRCA framework, which are not reproduced here.

This Statement is made under subsection 196B(2) of the Veterans’ Entitlements Act 1986, and it expressly applies to claims to which section 120A of the VEA or section 338 of the Military Rehabilitation and Compensation Act 2004 applies (section 3 and section 5). The Statement therefore functions as a medical‑evidentiary input into the statutory scheme of the VEA and MRCA. It does not itself amend those Acts, establish entitlement criteria outside them, nor create new statutory rights or obligations beyond its role in informing whether a reasonable hypothesis exists.

Interaction with the ICD‑10‑AM is specified. The instrument notes that although analgesic nephropathy attracts ICD‑10‑AM code N14.0, for the purposes of applying the Statement the meaning of analgesic nephropathy is that given in subsection 7(2) (section 7(2)). The instrument further clarifies that references to ICD‑10‑AM codes are references to the code assignment in the International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Australian Modification, Tenth Edition, effective 1 July 2017 (section 7(3)). That means codified clinical classification may be used for record‑keeping or cross‑reference, but the statutory definition in the Statement controls the assessment of the reasonable hypothesis.

The Statement explicitly contemplates interplay with other Statements of Principles. Section 11 says that where a factor in section 9 refers to an injury or disease covered by another Statement of Principles made under subsection 196B(2) of the VEA, the factors in that other Statement “apply in accordance with the terms of that Statement of Principles as in force from time to time.” In practice this requires decision‑makers to cross‑reference and apply provisions from multiple Statements where there is overlap. Because the instrument allows the other Statements to be applied “as in force from time to time”, newer or amended Statements that cover the referenced injury or disease will govern that cross‑reference.

There is a temporal interaction embedded in section 10(2). The factor in section 9(2) (inability to obtain appropriate clinical management) “applies only to material contribution to, or aggravation of, analgesic nephropathy where the person's analgesic nephropathy was suffered or contracted before or during (but did not arise out of) the person's relevant service.” This creates a specific legal interaction between the timing of disease onset and the legal concept of arising out of service. The Statement therefore requires a claimant and decision‑maker to parse dates and causal language under the VEA/MRCA frameworks when treating lack of clinical management during service as a causal contributor.

The instrument replaces the preceding Statement of Principles concerning analgesic nephropathy No. 77 of 2016 by explicit repeal (section 4). The new Statement is dated 15 April 2025 and commences on 19 May 2025 (sections 1 and 2). No other amendments to the text are listed within the instrument itself.

Because section 11 permits factors in other Statements of Principles “as in force from time to time” to apply when cross‑referenced, the Statement is designed to sit in a changing regulatory environment where other Statements may be amended separately. The instrument therefore anticipates future amendments to other Statements by allowing those Statements’ current terms to apply when referenced.

The instrument does not set out transitional arrangements, savings clauses, or retrospective application rules within the text provided. It is silent on how claims lodged before the commencement date are to be treated, other than the express repeal of the 2016 Statement. Determination of how the repeal and replacement affect ongoing claims will depend on statutory rules and policies in the VEA and MRCA frameworks outside the instrument’s text. Practitioners should therefore check the VEA and MRCA for any procedural provisions governing the effect of new Statements on existing claims, and for any administrative practice notes issued by the Department or the Repatriation Medical Authority upon release.

The Schedule contains definitions that support the instrument and should be read as part of it; the definition of “analgesic nephropathy” refers back to subsection 7(2), while the Schedule also updates definitions of “MRCA”, “relevant service”, “terminal event” and “VEA” (Schedule 1 - Dictionary). The Schedule is part of the instrument as published and thus forms part of the amendment history insofar as a replacement Statement updates definitional scaffolding compared with the 2016 instrument.

No other amendment instruments, consultation history, or version notes are provided in the text supplied. The instrument’s date and commencement are the only explicit temporal markers that indicate when the current Statement became operative and which prior Statement it replaced (sections 1, 2 and 4).

The Statement itself does not reference any litigation history, cases, or judicial findings. The statutory basis for the Authority to make Statements of Principles is cited (subsection 196B(2) of the VEA) but the instrument does not name or summarise any judicial decisions applying or construing earlier versions of this Statement or related Statements of Principles.

Accordingly, no precedent, reported decision, or formal litigation outcome is recorded in the text provided. Practitioners wishing to understand how tribunals or courts have treated similar Statements of Principles or the “reasonable hypothesis” standard will need to consult case law and decisions outside this instrument. The Statement does not supply that material and does not purport to be a summary of judicial interpretation.

Because the Statement replaces a 2016 Statement, it is possible that prior litigation may have engaged the earlier Statement’s content; however, the new instrument does not describe any such litigation, nor does it indicate whether changes were made in response to judicial findings. Any assessment of litigation history relevant to the interpretation or application of this Statement therefore requires independent research in the VEA/MRCA jurisprudence and administrative decisions, which are not contained in the instrument.

Several technical and evidentiary pitfalls for claimants and advisers are embedded in the instrument’s precise wording.

First, the statutory definition of analgesic nephropathy controls over the ICD‑10‑AM code. Even though the condition is associated with ICD‑10‑AM code N14.0, subsection 7(2) makes clear that the Statement’s textual definition is the operative meaning for claims assessment, and subsection 7(3) clarifies what is meant by referencing an ICD code. Practitioners should not assume that a diagnostic code alone will suffice; the morphological and consumption elements listed in subsection 7(2) must be addressed in evidence.

Second, the phenacetin thresholds in section 9 are numeric and specific. The two alternative exposure tests are (a) a total of at least 1 kg of phenacetin in a phenacetin‑containing analgesic before clinical onset, or (b) an average of at least 1 g/day of phenacetin in a phenacetin‑containing analgesic for a continuous period of at least two years immediately preceding clinical onset (section 9(1)). Historical quantification of phenacetin exposure is often difficult because over‑the‑counter compound analgesics were sold in mixed formulations and records may be scarce. The instrument’s Notes identify common product names and chemical synonyms for phenacetin (see Note 1 and Note 2 to section 9). Practitioners must therefore search historical pharmacy, retail, and clinician records for these product names and synonyms; colloquial or trade names that are not listed in the Note may also be relevant but will require careful proof to tie to phenacetin content.

Third, the alternative factor, “inability to obtain appropriate clinical management for analgesic nephropathy before clinical worsening” (section 9(2)), is described at a high level. The instrument does not define “appropriate clinical management” or set standards for what amounts to inability to obtain it. Moreover, section 10(2) limits the applicability of this factor to material contribution or aggravation where analgesic nephropathy was suffered or contracted before or during, but did not arise out of, relevant service. This creates a nuanced temporal and causal test: the claimant must show pre‑existing or concurrent disease and that absent appropriate management service contributed materially to its aggravation. Proving inability to obtain care during service may require contemporaneous medical records, service medical logs, evidence of local health facility capacity, or witness testimony , evidence that is often fragmentary for older claims.

Fourth, the instrument requires that any factor in section 9 be “related to the relevant service rendered by the person” (section 10(1)). The Schedule’s definition of “relevant service” is specific and limited to certain categories (Schedule 1 - Dictionary). This means that service outside those enumerated categories is not captured by the Statement. Practitioners must map service histories carefully to the Schedule’s categories to ensure the correct legal gate is met.

For claimants, advisers and medical reporters preparing materials for a VEA or MRCA claim that invokes analgesic nephropathy, the immediate compliance tasks are practical and evidentiary: establish the statutory diagnosis as defined, prove at least one of the section 9 factors, and show the relationship between the factor and the person’s relevant service in accordance with section 10(1). Below are concrete steps founded on the instrument’s text.

1. Establish the diagnostic elements in subsection 7(2).

   • Obtain and compile medical records, nephrology reports, pathology reports, imaging and biopsy results that speak to the morphological features listed: papillary necrosis, chronic interstitial nephritis, renal cortical atrophy and capillary sclerosis. Demonstrate a clinical state of loss of renal function.
   • Where diagnostic reports reference ICD‑10‑AM code N14.0, ensure the report also addresses the features the Statement requires, because subsection 7(2) controls the operative definition.

2. Prove phenacetin exposure where that is the relied factor (section 9(1)).

   • Quantify exposure in the terms the Statement specifies: either a cumulative total of at least 1 kg of phenacetin before clinical onset, or an average of at least 1 g/day for a continuous period of at least two years immediately preceding clinical onset.
   • Locate pharmacy dispensing records, receipts, prescription records, employer clinic records, contemporaneous diary entries, purchase records or credible witness testimony that can be calibrated to phenacetin quantities. Use the product names listed in the Statement’s Note (for example, Bex powder, Vincent’s powder, Empirin Compound, Bromo seltzer) and the chemical synonyms for phenacetin in Note 2 to broaden archival searches. Where compound formulations are involved, obtain formulation data or historical pharmacopeia records that show phenacetin concentration per dose to convert units into grams of phenacetin.

3. Where relying on inability to obtain appropriate clinical management (section 9(2)).

   • Assemble contemporaneous medical records and service medical logs showing treatment attempts, referrals, availability of care, and any documented inability to access care.
   • Collect contemporaneous evidence of the local health infrastructure during service, such as posting location medical descriptions, service routine medical schedules, or testimony from medical officers.